Latest Transformation News

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

Pointerra Limited reported strong FY25 Q4 results marked by new enterprise customers, a major US defense subcontract, and significant cashflow improvements. The company’s AI-enhanced digital twin platform is gaining traction across multiple sectors, setting the stage for growth in FY26.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Great Divide Mining has taken a decisive step towards becoming a near-term gold producer through a new joint venture with Dart Mining and securing a Queensland government grant for exploration.

Doctor Care Anywhere has reported a landmark positive operating and investing cash inflow in Q2 2025, alongside modest consultation growth and strategic service expansion. The company reiterates its ambitious revenue and profitability targets amid ongoing cost transformation.

Cluey Ltd has achieved its first-ever positive operating cash flow in Q4 FY25, marking a pivotal shift towards sustainable growth powered by AI innovation and expanded market reach.

CZR Resources has secured shareholder and regulatory approval to sell its Robe Mesa iron ore project for A$75 million, positioning the company to focus on promising gold and base metal exploration in Western Australia.

Dotz Nano has partnered with CarbonCapture Inc. to scale its high-performance direct air capture sorbent, while raising AU$1.2 million to fund its DotzEarth project amid ongoing funding timing challenges.

Blue Star Helium has raised A$4.5 million through a strategic institutional placement to fund the final stages of its Galactica helium project, aiming for production by late 2025.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Santa Fe Minerals advanced its gold and vanadium exploration projects in Western Australia while moving to acquire the Eburnea Gold Project in Cote D’Ivoire, contingent on a capital raise and shareholder approval.